Xarelto Defendants: Third Time Lucky
Xarelto Defendants: Third Time Lucky
Introduction
The third straight win for Xarelto defendants in the Xarelto MDL No. 2592 bellwether trial, boosts the defendant's stand regarding the safety and efficacy of Xarelto. Bayer released a statement saying, ''that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine.” This decision came in by the Mississippi federal jury in favor of the defendants: J&J's Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. The plaintiff alleged that the Prothrombin Time (PT) test which is used to assess a patient's risks for bleeding, was not informed and instructed to the doctors by the manufacturers. This was opposed by the defendant's say that the PT test was not scientifically reliable.
Comments
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
Categories: Roundup
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Categories: Zimmer Hip/Knee Replacement
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
Categories: Hernia Mesh
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…